G. E. Hardee

PHARMACOKINETICS OF A TUMOR NECROSIS FACTOR-α PHOSPHOROTHIOATE 2′-O-(2-METHOXYETHYL) MODIFIED ANTISENSE OLIGONUCLEOTIDE: COMPARISON ACROSS SPECIES

Richard S. Geary, Rosie Z. Yu, Tanya Watanabe et al. · Drug Metabolism and Disposition · 2003 · 162 citations

Improvement of the encapsulation efficiency of oligonucleotide-containing biodegradable microspheres

T Freytag, Andrei Dashevsky, Lloyd Tillman et al. · Journal of Controlled Release · 2000 · 132 citations

Encapsulation Efficiency, Micro-encapsulation

Low dose flunixin meglumine: Effects on eicosanoid production and clinical signs induced by experimental endotoxaemia in horses

Susan D. Semrad, G. E. Hardee, MARILYN M. HARDEE et al. · Equine Veterinary Journal · 1987 · 126 citations

Oral bioavailability and multiple dose tolerability of an antisense oligonucleotide tablet formulated with sodium caprate

Araz Raoof, Iain K. Cumming, Ching‐Leou Teng et al. · Journal of Pharmaceutical Sciences · 2004 · 78 citations

Pharmaceutical Science, Oral Bioavailability, Pharmacology +6

Flunixin meglumine given in small doses: Pharmacokinetics and prostaglandin inhibition in healthy horses

Susan D. Semrad, G. E. Hardee, Maris Hardee et al. · American Journal of Veterinary Research · 1985 · 75 citations

Animal Physiology, Veterinary Physiology, Flunixin Meglumine +15